Skip to content
Screener

4D Molecular Therapeutics FDMT Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$37.8M+24.8%
EyePoint, Inc. logo
EyePoint, Inc.EYPT
$2.55M+34.4%
Regenxbio logo
RegenxbioRGNX
$7.36M-8.6%
KLR
Kalaris TherapeuticsKLRS
$317K—
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$11.2M-15.6%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$11.66M+6.5%

Other financials

Income statement

See full
Revenue$3.0M+21,664%
Operating income-$73.6M-37.3%
Net income-$68.8M-43.3%
EPS (diluted)-$1.01-17.4%

Balance sheet

See full
Cash & equivalents$72.5M-45.7%
Total debt$20.5M-13.9%
Total equity$451.8M-3.8%
Total assets$512.9M-0.5%

Cash flow

See full
Operating cash flow-$68.1M-42.6%
CapEx--100%
Free cash flow-$68.1M-40.8%

Valuation

See full
Market cap$561.97M+119%
Enterprise value$510.02M+152%
P/S6.4×-7,758×

Profitability

See full
Operating margin-220.1%-110pp
Net margin-174,314.2%-62,763pp
FCF margin-154,209.2%-53,057pp

Returns & leverage

See full
Return on equity-45.4%+29.8pp
Debt / equity0×0.0×
Current ratio9.3×-3.0×

Where this comes from

Reported directly by 4D Molecular Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211939
Line itemMarch 31,2026December 31,2025
Accounts payable$14,692$11,159
Accrued and other current liabilities22,86626,874
Deferred revenue360360
Operating lease liabilities, current portion5,4865,592
Total current liabilities43,40443,985
Deferred revenue, net of current portion2,125745
Derivative liability370358
Operating lease liabilities, long-term portion15,04915,821

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is 4D Molecular Therapeutics's operating lease liabilities (current)?
4D Molecular Therapeutics (FDMT) reported operating lease liabilities (current) of $5.49M in Q1 2026.
How has 4D Molecular Therapeutics's operating lease liabilities (current) changed year-over-year?
4D Molecular Therapeutics's operating lease liabilities (current) decreased by 3.4% year-over-year, from $5.68M to $5.49M.
What is the long-term trend for 4D Molecular Therapeutics's operating lease liabilities (current)?
Over 5 years (2020 to 2025), 4D Molecular Therapeutics's operating lease liabilities (current) has grown at a 22.8% compound annual growth rate (CAGR), from $2M to $5.59M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about 4D Molecular Therapeutics's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude